Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
A review of 13 cases of MPN in younger patients sought to determine whether pegylated interferon, used to treat adult patients with these diseases, was appropriate for patients younger than 21.
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.